HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools
00
Days
00
Hours
00
Mins
00
Sec
Register Now!
Market News Stocks News ETF News Crypto News

Amneal Pharmaceuticals LLC

Contributing Author

Recent Articles by Amneal Pharmaceuticals LLC

Dec-02
Amneal to Participate in Upcoming Investor Conferences AMRX GlobeNewswire
Dec-02
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol AMRX GlobeNewswire
Dec-01
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% AMRX GlobeNewswire
Nov-13
Amneal Receives U.S. FDA Approval for Iohexol Injection AMRX GlobeNewswire
Oct-30
Amneal Reports Third Quarter 2025 Financial Results AMRX GlobeNewswire
Oct-29
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol AMRX GlobeNewswire
Oct-27
Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches AMRX GlobeNewswire
Sep-30
Amneal to Report Third Quarter 2025 Results on October 30, 2025 AMRX GlobeNewswire
Sep-26
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) AMRX GlobeNewswire
Sep-23
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% AMRX GlobeNewswire
Sep-11
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution AMRX GlobeNewswire
Sep-04
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension AMRX GlobeNewswire
Aug-05
Amneal Reports Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-21
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 AMRX GlobeNewswire
Jul-21
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results AMRX GlobeNewswire
Jul-09
Amneal to Report Second Quarter 2025 Results on August 5, 2025 AMRX GlobeNewswire
Jun-25
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences AMRX GlobeNewswire
Jun-12
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension AMRX GlobeNewswire
May-29
Amneal to Participate at Upcoming Investor Conferences in June AMRX GlobeNewswire
May-15
Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults AMRX GlobeNewswire
May-08
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. AMRX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.